Lakefront Biotherapeutics

Update in progress

LKFT (NasdaqGS)

Lakefront Biotherapeutics NV is a biotechnology company focused on oncology and immunology, operating mainly in the United States and Europe. Its pipeline includes GLPG3667 in phase 2 for dermatomyositis and systemic lupus erythematosus, GLPG5101 a CD19 CAR-T (point-of-care) in phase 1/2 for relapsed/refractory non-Hodgkin lymphoma, and GLPG5301 a BCMA CAR-T (point-of-care) in phase 1/2 for relapsed/refractory multiple myeloma. It collaborates with Gilead Sciences. Formerly Galapagos NV, renamed in May 2026. Established 1999, based in Mechelen, Belgium.